文献速递炎症性肠病

全国性炎症性肠病患者队列中严重感染与机会性感染风险及SARS-CoV-2对该风险的影响

Risk of severe and opportunistic infections and the impact of SARS-COV-2 on this risk in a nationwide cohort of patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2023-01-16

基于美国国家退伍军人事务医疗系统的回顾性队列研究,比较SARS-CoV-2大流行前后炎症性肠病患者的严重感染与机会性感染发生率。大流行前严重感染比例显著高于大流行期(5.1% vs 4.4%,p=0.002),机会性感染比例相似(0.3% vs 0.3%,p=0.82)。与5-氨基水杨酸相比,使用抗TNF、抗TNF+TP或维得利珠单抗的患者严重感染风险升高。

要点

  • 大流行前严重感染比例5.1%,大流行期4.4%,大流行前显著更高(p=0.002)。
  • 机会性感染比例大流行前0.3%与大流行期0.3%相似(p=0.82)。
  • 与5-ASA相比,抗TNF(HR=1.50)、抗TNF+TP(HR=1.56)、维得利珠单抗(HR=1.81)严重感染风险升高。

核心结论

  • 在全国性炎症性肠病患者队列中,严重感染风险可能受到SARS-CoV-2大流行导致的行为改变影响。

研究设计与样本

  • 回顾性队列研究,纳入美国国家退伍军人事务医疗系统的炎症性肠病患者,分为大流行前组(17,202例)和大流行期组(15,903例)。

主要发现

  • 大流行前组严重感染比例5.1%,大流行期组4.4%,大流行前组显著更高(p=0.002)。
  • 大流行前组机会性感染比例0.3%,大流行期组0.3%,两组相似(p=0.82)。
  • 与5-ASA相比,抗TNF组严重感染HR=1.50(95%CI 1.31-1.72),抗TNF+TP组HR=1.56(95%CI 1.24-1.95),维得利珠单抗组HR=1.81(95%CI 1.49-2.20),p>0.001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Inflammatory Bowel Disease (IBD) patients have adopted lifestyle modifications to prevent infection via SARS COV-2. AIMS: This study aims to examine rate of serious infections and opportunistic infections in the pre-pandemic and pandemic period, and to analyse if the risk associated with medications used to treat IBD were potentially modified by associated change in lifestyle. METHODS: We conducted a retrospective cohort study of patients from the US national Veteran Affairs Healthcare System (VAHS). Patients were stratified into two groups: pre-pandemic (prior to SARS COV-2 pandemic) and pandemic (during SARS COV-2 pandemic) and outcomes were measured in these groups. Primary outcome was occurrence of any serious infection. Secondary outcome was occurrence of any opportunistic infection. RESULTS: There were 17,202 IBD patients in the pre-pandemic era and 15,903 patients in the pandemic era. The pre-pandemic era had a significantly higher proportion of serious infections relative to the pandemic era (5.1% vs. 4.4%, p = 0.002). The proportion of opportunistic infections were similar between pre-pandemic and pandemic eras (0.3% vs. 0.3%, p = 0.82). Relative to 5-ASA, patients taking anti-TNF (HR = 1.50 (1.31-1.72)), anti-TNF+TP (HR = 1.56 (1.24-1.95)) or vedolizumab (HR = 1.81 (1.49-2.20)) had an increased hazard of serious infection (p > 0.001). CONCLUSION: In a nationwide cohort of IBD patients, we found that risk of serious infections could possibly be affected by behavioural modifications due to SARS-COV-2 pandemic.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Khan N, Mahmud N, Patel M, et al. Risk of severe and opportunistic infections and the impact of SARS-COV-2 on this risk in a nationwide cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2023. PMID: 36645110. doi:10.1111/apt.17393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。